Business programme

Healthcare of the Future: Gene Technologies and Personalized Medicine as an Industry Growth Driver

03 Jun , 09:00–10:15
New Technology Frontiers
Pavilion G, conference hall G6
In partnership with Takeda

The development of gene therapy technologies in medicine is undergoing a rapid surge, and the widespread clinical use of cell and gene technologies in modern medicine has opened up unprecedented possibilities in the battle against diseases once thought to be incurable. Meanwhile, issues surrounding the acceptability of altering the human genome have struck a nerve, raising social and ethical questions regarding interference in human evolution. The development of gene technologies is undoubtedly a matter of national security, and represents great medical progress. However, the need for government mechanisms to protect the rights and freedoms of human beings is clear. Which achievements in the realm of health diagnostic systems, innovative treatment algorithms, and medicines have been driven by the development of gene technologies? What real and prospective applications do gene technologies have in clinical practice? What innovative genetic studies are being conducted in Russia? What diseases could they help prevent in the near future, and what is the future of their development in the healthcare system? What are the possibilities and risks of research in the realm of editing the human genome? What are the prospects for their practical application in medicine?

Sergey Kutsev, Director, Research Centre for Medical Genetics; Chief External Expert in Medical Genetics of the Ministry of Health of the Russian Federation

Dmitry Artyukhov, Governor of Yamalo-Nenets Autonomous Region
Vladislav Baranov, General Director, Group of clinics "SOGAZ MEDICINA"
Lina Basel Salmon, Director, The Raphael Recanati Genetic Institute - Beilinson (online)
Dmitry Koloda, Medical Director, Takeda Russia
Mark Kurtser, General Director, Mother and Child Group of Companies (online)
Ning Li, Vice President, BGI Group (online)
Alexey Repik, Chairman, Delovaya Rossiya (Business Russia); Chairman of the Board, Group R-Pharm
Tatyana Semenova, Deputy Minister of Health of the Russian Federation
Veronika Skvortsova, Head, Federal Medical-Biological Agency of the Russian Federation
Mike Fraser, General Manager of Europe, Middle East and Africa, Novartis Gene Therapies (online)

Front row participants
Pavel Volchkov, Director, Institute of Personalized Medicine, National Medical Research Center for Endocrinology, Ministry of Health of the Russian Federation
Elena Zhidkova, Head, Central Healthcare Directorate, Russian Railways
Irina Zabolotnaya, Deputy Director of the Department of Social Policy, Norilsk Nickel
Olesya Sagaidak, Deputy Medical Director, EVOGEN; Researcher, Federal State Budgetary Institution "National Medical Research Center of Cardiology" of the Ministry of Health of Russia
Q.Annie Hasan, Consultant & HOD, Department of Genetics and Molecular Medicine, Kamineni Hospital, Hyderabad (online)